<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A01FD660-9141-46EE-9FFB-9236CE7FBFB4"><gtr:id>A01FD660-9141-46EE-9FFB-9236CE7FBFB4</gtr:id><gtr:name>University of Colorado (Denver)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Cancer Biology</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A01FD660-9141-46EE-9FFB-9236CE7FBFB4"><gtr:id>A01FD660-9141-46EE-9FFB-9236CE7FBFB4</gtr:id><gtr:name>University of Colorado (Denver)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/84AE0B99-4BC6-4F05-8C2B-E050830E7B72"><gtr:id>84AE0B99-4BC6-4F05-8C2B-E050830E7B72</gtr:id><gtr:name>AB SCIEX UK Limited</gtr:name><gtr:address><gtr:line1>Phoenix House</gtr:line1><gtr:line2>Lakeside Drive</gtr:line2><gtr:line3>Centre Park</gtr:line3><gtr:postCode>WA1 1RX</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2451E73A-707A-46CC-A356-16CB3B4653AE"><gtr:id>2451E73A-707A-46CC-A356-16CB3B4653AE</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Huang</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FM013782%2F1"><gtr:id>9154D76D-2C40-47E8-8204-650EE930DBE9</gtr:id><gtr:title>A toolkit for tyrosine kinase signalling network analysis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M013782/1</gtr:grantReference><gtr:abstractText>Tyrosine kinases (TKs) control multiple essential physiological processes including multi-cellular development and metabolic homeostasis. Deregulation of TKs and their associated downstream signalling cascades are key drivers in debilitating diseases such as diabetes and cancer. Consequently, the ability to accurately profile TK signalling events at a systems level is of considerable interest. Here we seek to develop a prototype Toolkit which measures TK signalling networks into a contract-based service and explore the further development of the technology as &amp;quot;kit&amp;quot;-based profiling products for non-specialist users. We envisage that this commercial service will be of interest to a broad range of investigators who wish to profile cellular signalling in multiple biological contexts. Furthermore, the development of a kit-based product will enable non-specialist investigators to perform such experiments using standard equipment found within proteomic core facilities.</gtr:abstractText><gtr:fund><gtr:end>2016-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>144051</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Colorado (Denver)</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:department>Division of Medical Oncology</gtr:department><gtr:description>Bioinformatics collaboration</gtr:description><gtr:id>BF01519E-B486-4890-84E2-BA3145EEA3E4</gtr:id><gtr:impact>Publication: Expanding the computational toolbox for interrogating cancer kinomes.
Tan AC, Ryall KA, Huang PH.
Pharmacogenomics. 2016 Jan;17(2):95-7.</gtr:impact><gtr:partnerContribution>Collaborators performed bioinformatic analysis</gtr:partnerContribution><gtr:piContribution>We have provided data on kinase signalling networks for bioinformatic analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>A tyrosine kinase signalling assay for measuring tyrosine phosphorylation in a quantitative and reproducible manner has been developed. The assay has been designed to quantitate phosphorylation of tyrosine residues in signalling networks of high relevance in cell line models of various cancers. The signalling proteins that we have included in the assay comprise: receptor tyrosine kinases, their cognate adaptor proteins and downstream integrators of signalling pathways. The expertise gained in developing this method will allow rapid adaptation to other signalling networks by the incorporation of additional peptides corresponding to relevant tyrosine phosphorylation sites. The use of scheduling in the mass spectrometer, where specific precursors are fragmented in narrow time windows throughout the Liquid Chromatography-Mass Spectrometry (LC/MS) run, means that a large number of phosphorylation sites can be quantitated in a single experiment and we will be able to analyse ~50 samples per week. The method has been successfully developed on the Thermo Fisher TSQ-Vantage triple quadrupole mass spectrometer platform.</gtr:description><gtr:exploitationPathways>We anticipate publishing this tool and results later this year which can be readily adopted by others in the research community. We are also evaluating the feasibility of providing a targeted assay commercial service for tyrosine kinase pathway analysis.</gtr:exploitationPathways><gtr:id>DCC6A628-8585-4110-B8B0-167B250D06BE</gtr:id><gtr:sectors><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B64EF6A1-28C8-481F-91FF-5134E871FFB3"><gtr:id>B64EF6A1-28C8-481F-91FF-5134E871FFB3</gtr:id><gtr:title>Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase.</gtr:title><gtr:parentPublicationTitle>New biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b3cf9fd6ad1400bb1aae0526652a70b"><gtr:id>4b3cf9fd6ad1400bb1aae0526652a70b</gtr:id><gtr:otherNames>Corallino S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1871-6784</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64696945-F0AB-4327-A90F-DE9AAE97BE4C"><gtr:id>64696945-F0AB-4327-A90F-DE9AAE97BE4C</gtr:id><gtr:title>Dual Targeting of PDGFRa and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9fa8b55578ae3549c308c0b82f97896a"><gtr:id>9fa8b55578ae3549c308c0b82f97896a</gtr:id><gtr:otherNames>Wong JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/M013782/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>